<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02212483</url>
  </required_header>
  <id_info>
    <org_study_id>35RC12_9713_ECENVIR</org_study_id>
    <secondary_id>2012-A01414-39</secondary_id>
    <secondary_id>12/42-875</secondary_id>
    <secondary_id>13.424</secondary_id>
    <secondary_id>913428</secondary_id>
    <nct_id>NCT02212483</nct_id>
  </id_info>
  <brief_title>Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients</brief_title>
  <acronym>ECENVIR</acronym>
  <official_title>Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients (ECENVIR Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ecole des Hautes Etudes en Santé Publique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Recherche et Documentation en Economie de la Santé, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asthma is one of the most prevalent chronic respiratory diseases, with potential&#xD;
      lifethreatening impacts. Indeed, asthma is still responsible for about a thousand deceases&#xD;
      per year in France, and constitutes a public health problem in our country as in many&#xD;
      countries in the world. The economic burden of asthma is also very high, in terms of health&#xD;
      care, and indirect costs including lost work and lost school days.&#xD;
&#xD;
      A few international and French studies have shown a positive clinical impact of Medical&#xD;
      Indoor Environment Counselors (MIECs) visiting homes of asthma patients, mainly pediatrics.&#xD;
      It has been proposed that MIECs could contribute to reduce patient exposure to many allergens&#xD;
      and irritants, among them, house dust mite allergens, formaldehyde or molds. Most of the&#xD;
      studies that show a significant decrease of hospitalization or visit in an emergency ward for&#xD;
      asthma are monocentric and study the eviction of 1 such identified risk factor. By contrast,&#xD;
      meta-analysis underline that additional studies are needed to evaluate the effectiveness of&#xD;
      these interventions in adults, in a multicentric and controlled manner, with both clinical,&#xD;
      environmental and economical endpoints.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology/Study schedule :&#xD;
&#xD;
      A prospective multicenter randomised, open label, controlled trial with blind evaluation of&#xD;
      the primary evaluation criterion on three parallel groups of patients.&#xD;
&#xD;
      Procedures :&#xD;
&#xD;
      Home intervention of MIECs that comprise diagnostic of allergen/irritant exposure (after&#xD;
      sampling), advices for allergen/irritant avoidance and follow up of advice compliance.&#xD;
&#xD;
      After randomisation and agreement of the patient and the family, the &quot; intervention group &quot;&#xD;
      will benefit from a first home intervention of a MIEC during the 4 weeks following inclusion,&#xD;
      then a final visit at the end of the study after 12 months.&#xD;
&#xD;
      Two comparative groups will be identified :&#xD;
&#xD;
        -  the &quot; control group &quot; who will benefit from a first home intervention of a MIEC but&#xD;
           without advices (only audit + sampling), then a final and a complete visit at the end of&#xD;
           the study&#xD;
&#xD;
        -  a &quot; non intervention &quot; group with no initial visit, but who will benefit from a complete&#xD;
           home intervention of a MIEC at the end of the study.&#xD;
&#xD;
      Substantial modification of the 20th of June, 2016 : Modification of the design : change into&#xD;
      a 2 parallel groups evaluation Justification: At its meeting of June 1, 2016, considering the&#xD;
      inclusion difficulties, the Scientific Council decided to give up the &quot;Control&quot; group.&#xD;
&#xD;
      The study design is then : a prospective multicenter randomised, open label, controlled trial&#xD;
      with blind evaluation of the primary evaluation criterion on three parallel groups of&#xD;
      patients.&#xD;
&#xD;
      The objective is to recruit 50 to 70 patients by arm.&#xD;
&#xD;
      Expected findings and impact :&#xD;
&#xD;
      If our hypothesis that home intervention of MIECs are cost-effective on asthma control, then&#xD;
      it is relevant to include such service in the medical care during the management of asthma&#xD;
      patients with a reimbursement by the social security.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 5, 2014</start_date>
  <completion_date type="Actual">March 5, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Substantial modification of the 20th of June, 2016 : Modification of the design : change into a 2 parallel groups evaluation Justification: At its meeting of June 1, 2016, considering the inclusion difficulties, the Scientific Council decided to give up the &quot;Control&quot; group.&#xD;
The study design is then : a prospective multicenter randomised, open label, controlled trial with blind evaluation of the primary evaluation criterion on three parallel groups of patients.&#xD;
The objective is to recruit 50 to 70 patients by arm.&#xD;
The Control group will still be described.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic pressure versus asthma control</measure>
    <time_frame>12 months</time_frame>
    <description>The primary objective of this study is to assess the efficacy of home interventions of MIECs on asthma control.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug consumption and medical care</measure>
    <time_frame>12 months</time_frame>
    <description>One of the secondary objectives is to compare the following after home interventions of MIECs, evolution of drug consumption and medical care needed by asthmatic patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Advices compliance</measure>
    <time_frame>12 months</time_frame>
    <description>One of the secondary objectives is to compare the following after home interventions of MIECs : compliance with advices of MIECs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>One of the secondary objectives is to compare the following after home interventions of MIECs : quality of life before and after home intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indoor pollutants concentrations</measure>
    <time_frame>12 months</time_frame>
    <description>One of the secondary objectives is to compare the following after home interventions of MIECs : evolution of exposure to indoor pollutants in the intervention group.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After randomisation and agreement of the patient and the family, the &quot; intervention group &quot; will benefit from a first home intervention of a MIEC during the 4 weeks following inclusion, then a final visit at the end of the study after 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The &quot; control group &quot; is one of the two comparative groups who will benefit from a first home intervention of a MIEC but without advices (only audit + sampling), then a final and a complete visit at the end of the study.&#xD;
This group has been suppressed with the last amendment. But data of the subjects included in this group will be analyzed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non intervention group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The &quot; non intervention &quot; group is the second comparative group with no initial visit, but will benefit from a complete home intervention of a MIEC at the end of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>First home intervention with advice</intervention_name>
    <description>A first home intervention of a MIEC during the 4 weeks following inclusion, with sampling, audit and advices.</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>First home intervention without any advice</intervention_name>
    <description>A first home intervention of a MIEC during the 4 weeks following inclusion, with sampling, home audit but without any advice.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Final home visit</intervention_name>
    <description>Final home visit at the end of the study after 12 months, with sampling and home audit.&#xD;
For the &quot;intervention group&quot;, checking of the advice compliance. For the both comparative groups, delivery of advices.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_label>Non intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age greater than or equal to 6 years and less than 45 (&lt;45 years),&#xD;
&#xD;
          -  patients with an eligible control level of asthma,&#xD;
&#xD;
          -  sensitization to one or more allergens demonstrated during the last 36 months with&#xD;
             prick tests (papules with a diameter &gt; 3 mm compared to a negative control or &gt; 50% of&#xD;
             positive control) and/or specific IgE detection (&gt; 0.10 U/mL),&#xD;
&#xD;
          -  patients &gt; 15 years presenting with a reversibility to ß2-agonists &gt; 200 mL and/or &gt;&#xD;
             12% compared to the initial FEV1 value (test performed at least once in life) or&#xD;
             patients ≥ 6 years and ≤ 15 years presenting with a reversibility to ß2-agonists &gt; 200&#xD;
             mL and/or &gt; 12% compared to the initial FEV1 value (at least once in the life) and/or&#xD;
             a positive metacholine challenge (at least once in the life),&#xD;
&#xD;
          -  patients sleeping &gt; 6 nights per week in the same house&#xD;
&#xD;
          -  individuals affiliated to 1 of the 3 French social security (for matching data from&#xD;
             French social security via SNIIRAM system),&#xD;
&#xD;
          -  Only one patient per dwelling,&#xD;
&#xD;
          -  Patient oral consent (written attestation by investigator)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  chronic obstructive pulmonary disease (COPD),&#xD;
&#xD;
          -  identified occupational asthma,&#xD;
&#xD;
          -  Move within the 6 months before home intervention or predicted during the first year&#xD;
             of inclusion,&#xD;
&#xD;
          -  advices provided during the 2 years before inclusion during a home intervention of a&#xD;
             MIEC&#xD;
&#xD;
          -  active smokers or smoker who given up smoking less than 5 years ago, with a&#xD;
             consumption of more than 10 years of 20 cigarettes/day, OR smoker who given up smoking&#xD;
             more than 5 years ago, with a consumption of more than 20 years of 20 cigarettes/day,&#xD;
&#xD;
          -  patients &lt; 18 years for whom the parents (or legal guardian) are opposed to the&#xD;
             inclusion in ECENVIR study,&#xD;
&#xD;
          -  Major people being the object of a legal protection (protection(saving) of justice,&#xD;
             guardianship, supervision(guardianship)) and private persons of freedom&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pierre Gangneux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Strasbourg UH</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aix-en-Provence Hospital</name>
      <address>
        <city>Aix-en-Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chalon</name>
      <address>
        <city>Chalon-sur-Saone</city>
        <zip>71100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chauny Hospital</name>
      <address>
        <city>Chauny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dijon University Hospital</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lille UH</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Macon Hospital</name>
      <address>
        <city>Macon</city>
        <zip>71018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marseille European Hospital</name>
      <address>
        <city>Marseille</city>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marseille University Hospital</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reims University Hospital</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vire Hospital</name>
      <address>
        <city>Vire</city>
        <zip>14504</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Le Cann P, Paulus H, Glorennec P, Le Bot B, Frain S, Gangneux JP. Home Environmental Interventions for the Prevention or Control of Allergic and Respiratory Diseases: What Really Works. J Allergy Clin Immunol Pract. 2017 Jan-Feb;5(1):66-79. doi: 10.1016/j.jaip.2016.07.011. Epub 2016 Sep 21.</citation>
    <PMID>27665387</PMID>
  </results_reference>
  <results_reference>
    <citation>Gangneux JP, Bouvrais M, Frain S, Morel H, Deguen S, Chevrier S, Le Cann P. Asthma and Indoor Environment: Usefulness of a Global Allergen Avoidance Method on Asthma Control and Exposure to Molds. Mycopathologia. 2020 Apr;185(2):367-371. doi: 10.1007/s11046-019-00417-9. Epub 2020 Jan 2.</citation>
    <PMID>31897973</PMID>
  </results_reference>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>August 5, 2014</study_first_submitted>
  <study_first_submitted_qc>August 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2014</study_first_posted>
  <last_update_submitted>May 22, 2023</last_update_submitted>
  <last_update_submitted_qc>May 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Medical Indoor Environment Counselors</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Environment</keyword>
  <keyword>Clinical effectiveness</keyword>
  <keyword>Economical impact</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02212483
org study id: 35RC12_9713_ECENVIR
secondary id: 2012-A01414-39
secondary id: 12/42-875
secondary id: 13.424
secondary id: 913428
nct id: NCT02212483
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
has dmc: No
Asthma is one of the most prevalent chronic respiratory diseases, with potential
      lifethreatening impacts. Indeed, asthma is still responsible for about a thousand deceases
      per year in France, and constitutes a public health problem in our country as in many
      countries in the world. The economic burden of asthma is also very high, in terms of health
      care, and indirect costs including lost work and lost school days.

      A few international and French studies have shown a positive clinical impact of Medical
      Indoor Environment Counselors (MIECs) visiting homes of asthma patients, mainly pediatrics.
      It has been proposed that MIECs could contribute to reduce patient exposure to many allergens
      and irritants, among them, house dust mite allergens, formaldehyde or molds. Most of the
      studies that show a significant decrease of hospitalization or visit in an emergency ward for
      asthma are monocentric and study the eviction of 1 such identified risk factor. By contrast,
      meta-analysis underline that additional studies are needed to evaluate the effectiveness of
      these interventions in adults, in a multicentric and controlled manner, with both clinical,
      environmental and economical endpoints.
Methodology/Study schedule :

      A prospective multicenter randomised, open label, controlled trial with blind evaluation of
      the primary evaluation criterion on three parallel groups of patients.

      Procedures :

      Home intervention of MIECs that comprise diagnostic of allergen/irritant exposure (after
      sampling), advices for allergen/irritant avoidance and follow up of advice compliance.

      After randomisation and agreement of the patient and the family, the " intervention group "
      will benefit from a first home intervention of a MIEC during the 4 weeks following inclusion,
      then a final visit at the end of the study after 12 months.

      Two comparative groups will be identified :

        -  the " control group " who will benefit from a first home intervention of a MIEC but
           without advices (only audit + sampling), then a final and a complete visit at the end of
           the study

        -  a " non intervention " group with no initial visit, but who will benefit from a complete
           home intervention of a MIEC at the end of the study.

      Substantial modification of the 20th of June, 2016 : Modification of the design : change into
      a 2 parallel groups evaluation Justification: At its meeting of June 1, 2016, considering the
      inclusion difficulties, the Scientific Council decided to give up the "Control" group.

      The study design is then : a prospective multicenter randomised, open label, controlled trial
      with blind evaluation of the primary evaluation criterion on three parallel groups of
      patients.

      The objective is to recruit 50 to 70 patients by arm.

      Expected findings and impact :

      If our hypothesis that home intervention of MIECs are cost-effective on asthma control, then
      it is relevant to include such service in the medical care during the management of asthma
      patients with a reimbursement by the social security.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Supportive Care
masking: Single (Outcomes Assessor)
masking description: Substantial modification of the 20th of June, 2016 : Modification of the design : change into a 2 parallel groups evaluation Justification: At its meeting of June 1, 2016, considering the inclusion difficulties, the Scientific Council decided to give up the "Control" group.
The study design is then : a prospective multicenter randomised, open label, controlled trial with blind evaluation of the primary evaluation criterion on three parallel groups of patients.
The objective is to recruit 50 to 70 patients by arm.
The Control group will still be described.
measure: Therapeutic pressure versus asthma control
time frame: 12 months
description: The primary objective of this study is to assess the efficacy of home interventions of MIECs on asthma control.
measure: Drug consumption and medical care
time frame: 12 months
description: One of the secondary objectives is to compare the following after home interventions of MIECs, evolution of drug consumption and medical care needed by asthmatic patients.
measure: Advices compliance
time frame: 12 months
description: One of the secondary objectives is to compare the following after home interventions of MIECs : compliance with advices of MIECs.
measure: Quality of life questionnaire
time frame: 12 months
description: One of the secondary objectives is to compare the following after home interventions of MIECs : quality of life before and after home intervention.
measure: Indoor pollutants concentrations
time frame: 12 months
description: One of the secondary objectives is to compare the following after home interventions of MIECs : evolution of exposure to indoor pollutants in the intervention group.
arm group label: Intervention group
arm group type: Experimental
description: After randomisation and agreement of the patient and the family, the " intervention group " will benefit from a first home intervention of a MIEC during the 4 weeks following inclusion, then a final visit at the end of the study after 12 months.
arm group label: Control group
arm group type: Active Comparator
description: The " control group " is one of the two comparative groups who will benefit from a first home intervention of a MIEC but without advices (only audit + sampling), then a final and a complete visit at the end of the study.
This group has been suppressed with the last amendment. But data of the subjects included in this group will be analyzed.
arm group label: Non intervention group
arm group type: Other
description: The " non intervention " group is the second comparative group with no initial visit, but will benefit from a complete home intervention of a MIEC at the end of the study.
intervention type: Other
intervention name: First home intervention with advice
description: A first home intervention of a MIEC during the 4 weeks following inclusion, with sampling, audit and advices.
arm group label: Intervention group
intervention type: Other
intervention name: First home intervention without any advice
description: A first home intervention of a MIEC during the 4 weeks following inclusion, with sampling, home audit but without any advice.
arm group label: Control group
intervention type: Other
intervention name: Final home visit
description: Final home visit at the end of the study after 12 months, with sampling and home audit.
For the "intervention group", checking of the advice compliance. For the both comparative groups, delivery of advices.
arm group label: Control group
arm group label: Intervention group
arm group label: Non intervention group
criteria: 
gender: All
minimum age: 6 Years
maximum age: 44 Years
healthy volunteers: No
last name: Jean-Pierre Gangneux, MD
role: Principal Investigator
affiliation: Rennes University Hospital
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: France
citation: Le Cann P, Paulus H, Glorennec P, Le Bot B, Frain S, Gangneux JP. Home Environmental Interventions for the Prevention or Control of Allergic and Respiratory Diseases: What Really Works. J Allergy Clin Immunol Pract. 2017 Jan-Feb;5(1):66-79. doi: 10.1016/j.jaip.2016.07.011. Epub 2016 Sep 21.
PMID: 27665387
citation: Gangneux JP, Bouvrais M, Frain S, Morel H, Deguen S, Chevrier S, Le Cann P. Asthma and Indoor Environment: Usefulness of a Global Allergen Avoidance Method on Asthma Control and Exposure to Molds. Mycopathologia. 2020 Apr;185(2):367-371. doi: 10.1007/s11046-019-00417-9. Epub 2020 Jan 2.
PMID: 31897973
responsible party type: Sponsor
mesh term: Asthma